Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 169 to 180 of 180 entries
Sorted by: Best Match Show Resources per page
Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria.

Vaccine

Jean Baptiste AE, Bawa S, Oteri AJ, Dieng B, Shuaib F, Mulombo WK, ÖZTÜRK N, ALTAN EB, Sema TAN.
PMID: 34531080
Vaccine. 2021 Nov 17;39:C1-C2. doi: 10.1016/j.vaccine.2021.08.084. Epub 2021 Sep 13.

No abstract available.

Cite
Jean Baptiste AE, Bawa S, Oteri AJ, et al. Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria. Vaccine. 2021;39:C1-C2doi: 10.1016/j.vaccine.2021.08.084.
Jean Baptiste, A. E., Bawa, S., Oteri, A. J., Dieng, B., Shuaib, F., Mulombo, W. K., ÖZTÜRK, N., ALTAN, E. B., & Sema, T. A. N. (2021). Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria. Vaccine, 39C1-C2. https://doi.org/10.1016/j.vaccine.2021.08.084
Jean Baptiste, Anne Eudes, et al. "Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria." Vaccine vol. 39 (2021): C1-C2. doi: https://doi.org/10.1016/j.vaccine.2021.08.084
Jean Baptiste AE, Bawa S, Oteri AJ, Dieng B, Shuaib F, Mulombo WK, ÖZTÜRK N, ALTAN EB, Sema TAN. Nationwide measles supplementary immunization activities to increase immunity levels in Nigeria. Vaccine. 2021 Nov 17;39:C1-C2. doi: 10.1016/j.vaccine.2021.08.084. Epub 2021 Sep 13. PMID: 34531080.
Copy Download .nbib Format: NLM
Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study.

BMJ open ophthalmology

Yip JLY, Muthy Z, Peto T, Lotery A, Foster PJ, Patel P.
PMID: 33693059
BMJ Open Ophthalmol. 2021 Feb 23;6(1):e000585. doi: 10.1136/bmjophth-2020-000585. eCollection 2021.

OBJECTIVE: There is contrasting evidence on the relationship between socioeconomic status (SES) and age-related macular degeneration (AMD), the most common cause of visual impairment (VI) in developed countries. This study examines the relationship between SES, cardiovascular risk factors and...

Cite
Yip JLY, Muthy Z, Peto T, et al. Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study. BMJ Open Ophthalmol. 2021;6(1):e000585doi: 10.1136/bmjophth-2020-000585.
Yip, J. L. Y., Muthy, Z., Peto, T., Lotery, A., Foster, P. J., Patel, P. (2021). Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study. BMJ open ophthalmology, 6(1), e000585. https://doi.org/10.1136/bmjophth-2020-000585
Yip, Jennifer Lai Yee, et al. "Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study." BMJ open ophthalmology vol. 6,1 (2021): e000585. doi: https://doi.org/10.1136/bmjophth-2020-000585
Yip JLY, Muthy Z, Peto T, Lotery A, Foster PJ, Patel P. Socioeconomic risk factors and age-related macular degeneration in the UK Biobank study. BMJ Open Ophthalmol. 2021 Feb 23;6(1):e000585. doi: 10.1136/bmjophth-2020-000585. eCollection 2021. PMID: 33693059; PMCID: PMC7907888.
Copy Download .nbib Format: NLM
The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer.

BJS open

Davey MG, Ryan ÉJ, Folan PJ, O'Halloran N, Boland MR, Barry MK, Sweeney KJ, Malone CM, McLaughlin RJ, Kerin MJ, Lowery AJ.
PMID: 34013318
BJS Open. 2021 May 07;5(3). doi: 10.1093/bjsopen/zrab040.

BACKGROUND: Oestrogen receptor (ER) status provides invaluable prognostic and therapeutic information in breast cancer (BC). When clinical decision making is driven by ER status, the value of progesterone receptor (PgR) status is less certain. The aim of this study...

Cite
Davey MG, Ryan ÉJ, Folan PJ, et al. The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. BJS Open. 2021;5(3)doi: 10.1093/bjsopen/zrab040.
Davey, M. G., Ryan, �. �. J., Folan, P. J., O'Halloran, N., Boland, M. R., Barry, M. K., Sweeney, K. J., Malone, C. M., McLaughlin, R. J., Kerin, M. J., & Lowery, A. J. (2021). The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. BJS open, 5(3), . https://doi.org/10.1093/bjsopen/zrab040
Davey, M G, et al. "The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer." BJS open vol. 5,3 (2021). doi: https://doi.org/10.1093/bjsopen/zrab040
Davey MG, Ryan ÉJ, Folan PJ, O'Halloran N, Boland MR, Barry MK, Sweeney KJ, Malone CM, McLaughlin RJ, Kerin MJ, Lowery AJ. The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. BJS Open. 2021 May 07;5(3). doi: 10.1093/bjsopen/zrab040. PMID: 34013318; PMCID: PMC8134515.
Copy Download .nbib Format: NLM
General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital.

Irish journal of medical science

Davey MG, O'Donnell JPM, Maher E, McMenamin C, McAnena PF, Kerin MJ, Miller N, Lowery AJ.
PMID: 34595690
Ir J Med Sci. 2021 Sep 30; doi: 10.1007/s11845-021-02789-8. Epub 2021 Sep 30.

BACKGROUND: Europe's General Data Protection Regulation, or GDPR, is a set of data protection rules on the acquisition, storage, use, and access of personal data. GDPR came into effect in May 2018 when it was introduced across all 27...

Cite
Davey MG, O'Donnell JPM, Maher E, et al. General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital. Ir J Med Sci. 2021;doi: 10.1007/s11845-021-02789-8.
Davey, M. G., O'Donnell, J. P. M., Maher, E., McMenamin, C., McAnena, P. F., Kerin, M. J., Miller, N., & Lowery, A. J. (2021). General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital. Irish journal of medical science, . https://doi.org/10.1007/s11845-021-02789-8
Davey, Matthew G, et al. "General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital." Irish journal of medical science vol. (2021). doi: https://doi.org/10.1007/s11845-021-02789-8
Davey MG, O'Donnell JPM, Maher E, McMenamin C, McAnena PF, Kerin MJ, Miller N, Lowery AJ. General data protection regulations (2018) and clinical research: perspectives of patients and doctors in an Irish university teaching hospital. Ir J Med Sci. 2021 Sep 30; doi: 10.1007/s11845-021-02789-8. Epub 2021 Sep 30. PMID: 34595690.
Copy Download .nbib Format: NLM
The Wavelia Microwave Breast Imaging system-tumour discriminating features and their clinical usefulness.

The British journal of radiology

Moloney BM, McAnena PF, Elwahab SM, Fasoula A, Duchesne L, Gil Cano JD, Glynn C, O'Connell A, Ennis R, Lowery AJ, Kerin MJ.
PMID: 34581186
Br J Radiol. 2021 Dec;94(1128):20210907. doi: 10.1259/bjr.20210907. Epub 2021 Oct 05.

OBJECTIVE: The Wavelia Microwave Breast Imaging (MBI) system, based on non-ionising imaging technology, has demonstrated exciting potential in the detection and localisation of breast pathology in symptomatic patients. In this study, the ability of the system to accurately estimate...

Cite
Moloney BM, McAnena PF, Elwahab SM, et al. The Wavelia Microwave Breast Imaging system-tumour discriminating features and their clinical usefulness. Br J Radiol. 2021;94(1128):20210907doi: 10.1259/bjr.20210907.
Moloney, B. M., McAnena, P. F., Elwahab, S. M., Fasoula, A., Duchesne, L., Gil Cano, J. D., Glynn, C., O'Connell, A., Ennis, R., Lowery, A. J., & Kerin, M. J. (2021). The Wavelia Microwave Breast Imaging system-tumour discriminating features and their clinical usefulness. The British journal of radiology, 94(1128), 20210907. https://doi.org/10.1259/bjr.20210907
Moloney, Brian M, et al. "The Wavelia Microwave Breast Imaging system-tumour discriminating features and their clinical usefulness." The British journal of radiology vol. 94,1128 (2021): 20210907. doi: https://doi.org/10.1259/bjr.20210907
Moloney BM, McAnena PF, Elwahab SM, Fasoula A, Duchesne L, Gil Cano JD, Glynn C, O'Connell A, Ennis R, Lowery AJ, Kerin MJ. The Wavelia Microwave Breast Imaging system-tumour discriminating features and their clinical usefulness. Br J Radiol. 2021 Dec;94(1128):20210907. doi: 10.1259/bjr.20210907. Epub 2021 Oct 05. PMID: 34581186; PMCID: PMC8631021.
Copy Download .nbib Format: NLM
Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study.

Eye (London, England)

Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J.
PMID: 33972705
Eye (Lond). 2021 May 10; doi: 10.1038/s41433-021-01542-w. Epub 2021 May 10.

BACKGROUND: This study aimed to assess the long-term effectiveness of the 0.2 μg/day fluocinolone acetonide (FAc) implant over ≥3 years for patients with diabetic macular oedema.METHODS: A retrospective audit of pseudo-anonymised data from patients with chronic diabetic macular oedema...

Cite
Bailey C, Chakravarthy U, Lotery A, et al. Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye (Lond). 2021;doi: 10.1038/s41433-021-01542-w.
Bailey, C., Chakravarthy, U., Lotery, A., Menon, G., Talks, J. (2021). Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye (London, England), . https://doi.org/10.1038/s41433-021-01542-w
Bailey, Clare, et al. "Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study." Eye (London, England) vol. (2021). doi: https://doi.org/10.1038/s41433-021-01542-w
Bailey C, Chakravarthy U, Lotery A, Menon G, Talks J. Extended real-world experience with the ILUVIEN® (fluocinolone acetonide) implant in the United Kingdom: 3-year results from the Medisoft® audit study. Eye (Lond). 2021 May 10; doi: 10.1038/s41433-021-01542-w. Epub 2021 May 10. PMID: 33972705; PMCID: PMC8107780.
Copy Download .nbib Format: NLM
Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study.

PharmacoEconomics

Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Yang Y, Lotery A, Williams M, Brazier J.
PMID: 34148190
Pharmacoeconomics. 2021 Sep;39(9):1099. doi: 10.1007/s40273-021-01057-y.

No abstract available.

Cite
Pennington B, Alshreef A, Flight L, et al. Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. Pharmacoeconomics. 2021;39(9):1099doi: 10.1007/s40273-021-01057-y.
Pennington, B., Alshreef, A., Flight, L., Metry, A., Poku, E., Hykin, P., Sivaprasad, S., Prevost, A. T., Vasconcelos, J. C., Murphy, C., Kelly, J., Yang, Y., Lotery, A., Williams, M., & Brazier, J. (2021). Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. PharmacoEconomics, 39(9), 1099. https://doi.org/10.1007/s40273-021-01057-y
Pennington, Becky, et al. "Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study." PharmacoEconomics vol. 39,9 (2021): 1099. doi: https://doi.org/10.1007/s40273-021-01057-y
Pennington B, Alshreef A, Flight L, Metry A, Poku E, Hykin P, Sivaprasad S, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Yang Y, Lotery A, Williams M, Brazier J. Correction to: Cost Effectiveness of Ranibizumab vs Aflibercept vs Bevacizumab for the Treatment of Macular Oedema Due to Central Retinal Vein Occlusion: The LEAVO Study. Pharmacoeconomics. 2021 Sep;39(9):1099. doi: 10.1007/s40273-021-01057-y. PMID: 34148190; PMCID: PMC8352804.
Copy Download .nbib Format: NLM
Macular thickness varies with age-related macular degeneration genetic risk variants in the UK Biobank cohort.

Scientific reports

Kaye RA, Patasova K, Patel PJ, Hysi P, Lotery AJ.
PMID: 34853365
Sci Rep. 2021 Dec 01;11(1):23255. doi: 10.1038/s41598-021-02631-2.

To evaluate the influence AMD risk genomic variants have on macular thickness in the normal population. UK Biobank participants with no significant ocular history were included using the UK Biobank Resource (project 2112). Spectral-domain optical coherence tomography (SD-OCT) images...

Cite
Kaye RA, Patasova K, Patel PJ, et al. Macular thickness varies with age-related macular degeneration genetic risk variants in the UK Biobank cohort. Sci Rep. 2021;11(1):23255doi: 10.1038/s41598-021-02631-2.
Kaye, R. A., Patasova, K., Patel, P. J., Hysi, P., Lotery, A. J. (2021). Macular thickness varies with age-related macular degeneration genetic risk variants in the UK Biobank cohort. Scientific reports, 11(1), 23255. https://doi.org/10.1038/s41598-021-02631-2
Kaye, Rebecca A, et al. "Macular thickness varies with age-related macular degeneration genetic risk variants in the UK Biobank cohort." Scientific reports vol. 11,1 (2021): 23255. doi: https://doi.org/10.1038/s41598-021-02631-2
Kaye RA, Patasova K, Patel PJ, Hysi P, Lotery AJ. Macular thickness varies with age-related macular degeneration genetic risk variants in the UK Biobank cohort. Sci Rep. 2021 Dec 01;11(1):23255. doi: 10.1038/s41598-021-02631-2. PMID: 34853365; PMCID: PMC8636487.
Copy Download .nbib Format: NLM
The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD.

Eye (London, England)

Khan AH, Pierce CO, De Salvo G, Griffiths H, Nelson M, Cree AJ, Menon G, Lotery AJ.
PMID: 34750590
Eye (Lond). 2021 Nov 08; doi: 10.1038/s41433-021-01824-3. Epub 2021 Nov 08.

BACKGROUND/OBJECTIVES: Systemic levels of pro-inflammatory cytokines and activated complement components affect the risk and/or progression of neovascular age-related macular degeneration (AMD). This study investigated the effect of serum pro-inflammatory cytokine levels and complement pathway activity on the clinical response...

Cite
Khan AH, Pierce CO, De Salvo G, et al. The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD. Eye (Lond). 2021;doi: 10.1038/s41433-021-01824-3.
Khan, A. H., Pierce, C. O., De Salvo, G., Griffiths, H., Nelson, M., Cree, A. J., Menon, G., & Lotery, A. J. (2021). The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD. Eye (London, England), . https://doi.org/10.1038/s41433-021-01824-3
Khan, Adnan H, et al. "The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD." Eye (London, England) vol. (2021). doi: https://doi.org/10.1038/s41433-021-01824-3
Khan AH, Pierce CO, De Salvo G, Griffiths H, Nelson M, Cree AJ, Menon G, Lotery AJ. The effect of systemic levels of TNF-alpha and complement pathway activity on outcomes of VEGF inhibition in neovascular AMD. Eye (Lond). 2021 Nov 08; doi: 10.1038/s41433-021-01824-3. Epub 2021 Nov 08. PMID: 34750590.
Copy Download .nbib Format: NLM
Hydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles.

Biomedicines

Chabria Y, Duffy GP, Lowery AJ, Dwyer RM.
PMID: 34829923
Biomedicines. 2021 Nov 15;9(11). doi: 10.3390/biomedicines9111694.

Synthetic and naturally occurring nano-sized particles present versatile vehicles for the delivery of therapy in a range of clinical settings. Their small size and modifiable physicochemical properties support refinement of targeting capabilities, immune response, and therapeutic cargo, but rapid...

Cite
Chabria Y, Duffy GP, Lowery AJ, et al. Hydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles. Biomedicines. 2021;9(11)doi: 10.3390/biomedicines9111694.
Chabria, Y., Duffy, G. P., Lowery, A. J., & Dwyer, R. M. (2021). Hydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles. Biomedicines, 9(11), . https://doi.org/10.3390/biomedicines9111694
Chabria, Yashna, et al. "Hydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles." Biomedicines vol. 9,11 (2021). doi: https://doi.org/10.3390/biomedicines9111694
Chabria Y, Duffy GP, Lowery AJ, Dwyer RM. Hydrogels: 3D Drug Delivery Systems for Nanoparticles and Extracellular Vesicles. Biomedicines. 2021 Nov 15;9(11). doi: 10.3390/biomedicines9111694. PMID: 34829923; PMCID: PMC8615452.
Copy Download .nbib Format: NLM
Risk Stratification Algorithm for Orthopedic Trauma Patients at Risk for Fat Embolism Syndrome.

Indian journal of orthopaedics

Lowery A, Naran V, Ames R, Patel A, Ramsey F, Slattery B, Pazionis T.
PMID: 34194642
Indian J Orthop. 2021 Feb 08;55(4):879-885. doi: 10.1007/s43465-021-00365-x. eCollection 2021 Aug.

BACKGROUND: Fat embolism syndrome (FES) is commonly reported in the setting of long bone and pelvic fractures, but the etiology and pathogenesis are unclear. The aim of this study was to identify clinical characteristics and laboratory findings that may...

Cite
Lowery A, Naran V, Ames R, et al. Risk Stratification Algorithm for Orthopedic Trauma Patients at Risk for Fat Embolism Syndrome. Indian J Orthop. 2021;55(4):879-885doi: 10.1007/s43465-021-00365-x.
Lowery, A., Naran, V., Ames, R., Patel, A., Ramsey, F., Slattery, B., & Pazionis, T. (2021). Risk Stratification Algorithm for Orthopedic Trauma Patients at Risk for Fat Embolism Syndrome. Indian journal of orthopaedics, 55(4), 879-885. https://doi.org/10.1007/s43465-021-00365-x
Lowery, Andrew, et al. "Risk Stratification Algorithm for Orthopedic Trauma Patients at Risk for Fat Embolism Syndrome." Indian journal of orthopaedics vol. 55,4 (2021): 879-885. doi: https://doi.org/10.1007/s43465-021-00365-x
Lowery A, Naran V, Ames R, Patel A, Ramsey F, Slattery B, Pazionis T. Risk Stratification Algorithm for Orthopedic Trauma Patients at Risk for Fat Embolism Syndrome. Indian J Orthop. 2021 Feb 08;55(4):879-885. doi: 10.1007/s43465-021-00365-x. eCollection 2021 Aug. PMID: 34194642; PMCID: PMC8192641.
Copy Download .nbib Format: NLM
A proteomic analysis of liver after ethanol binge in chronically ethanol treated rats.

Proteome science

Aroor AR, Roy LJ, Restrepo RJ, Mooney BP, Shukla SD.
PMID: 22545783
Proteome Sci. 2012 Apr 30;10(1):29. doi: 10.1186/1477-5956-10-29.

BACKGROUND: Binge ethanol in rats after chronic ethanol exposure augments necrosis and steatosis in the liver. In this study, two-dimensional gel electrophoresis proteomic profiles of liver of control, chronic ethanol, control-binge, and chronic ethanol- binge were compared.RESULTS: The proteomic...

Cite
Aroor AR, Roy LJ, Restrepo RJ, et al. A proteomic analysis of liver after ethanol binge in chronically ethanol treated rats. Proteome Sci. 2012;10(1):29doi: 10.1186/1477-5956-10-29.
Aroor, A. R., Roy, L. J., Restrepo, R. J., Mooney, B. P., & Shukla, S. D. (2012). A proteomic analysis of liver after ethanol binge in chronically ethanol treated rats. Proteome science, 10(1), 29. https://doi.org/10.1186/1477-5956-10-29
Aroor, Annayya R, et al. "A proteomic analysis of liver after ethanol binge in chronically ethanol treated rats." Proteome science vol. 10,1 (2012): 29. doi: https://doi.org/10.1186/1477-5956-10-29
Aroor AR, Roy LJ, Restrepo RJ, Mooney BP, Shukla SD. A proteomic analysis of liver after ethanol binge in chronically ethanol treated rats. Proteome Sci. 2012 Apr 30;10(1):29. doi: 10.1186/1477-5956-10-29. PMID: 22545783; PMCID: PMC3504578.
Copy Download .nbib Format: NLM
Showing 169 to 180 of 180 entries